title: [A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
abstract: We reviewed and analyzed the clinical data for a patient with metastatic castration-resistant prostate cancer (mCRPC) from September, 2009 to December, 2014. After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. tPSA or fPSA fluctuated between  30 and 50 ng/mL or between 10 and 20 ng/mL. MRI showed the left peripheral zone reduced. MRI and bone single photon emission computed tomography (SPECT) scan showed no new metastasis. These results indicated that application of abiraterone for patient with mCRPC not only decreased prostate specific antigen (PSA) levels and tumor volume, but also blocked bone metastasis progression and enhanced pain relief.
authors.affiliation: Department of Urology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Liuxun
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Urology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Long
authors.affiliation: Department of Urology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Leye
authors.initials: L
authors.lastname: He
mesh_terms: D000736:Androstenes / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018450:Disease Progression; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000736:Androstenes; D017430:Prostate-Specific Antigen; C089740:abiraterone